← Leaderboards
Jean-Claude Bystryn
New York University School Of Medicine
$2,442,177
Attributed
$2,442,177
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $607.5K · FY2005–09$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$1,780,018 · 5
FDA$662,159 · 1
By mechanism
R01$2,085,799 · 3
R21$276,378 · 1
R13$80,000 · 2
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Fred Valentine$14,208,248
- Bruce Neil Cronstein$53,680,413
- Howard S Hochster$9,390,994
- Kwok Kin Wong$31,472,345
- John P Rotrosen$35,649,271
Others in their field
Top investigators on “Patient Oriented Research”
- Praduman Jain · Vignet, Inc.$103,566,231
- Larry Arthur$103,000,000
- Charles A Coltman · Southwest Oncology Group$87,961,334
- Gregory H Reaman · National Childhood Cancer Foundation$61,988,461
- Steven E Reis · University Of Pittsburgh At Pittsburgh$61,626,874
- Steven M. Dubinett · Va Greater Los Angeles Healthcare System$57,862,577
Research focus
Patient Oriented ResearchHuman SubjectVaccine DevelopmentLiposomesNeoplasm /Cancer VaccineMelanomaInterleukin 2Colony Stimulating FactorAntitumor AntibodyWestern BlottingsNonhuman Therapy EvaluationNeoplasm /Cancer ImmunotherapyTumor AntigensLaboratory MouseGuinea PigsHuman Therapy EvaluationMeeting /Conference /SymposiumClinical ManagementCase-Control StudiesAutoantibodyCaringDelayed HypersensitivityBiotechnologyAdjuvant Therapy
Grant awards (9)
PHASE II RANDOMIZED TRIAL OF IVIG WITH OR WITHOUT CYCLOPHOSPHAMIDE IN PEMPHIGUS$331,059
R01 · FY2009 · FD · contact PI
PHASE II RANDOMIZED TRIAL OF IVIG WITH OR WITHOUT CYCLOPHOSPHAMIDE IN PEMPHIGUS$331,100
R01 · FY2007 · FD · contact PI
SERUM CYT-MAA AS AN EARLY MARKER OF RESPONSE TO THERAPY IN RESECTED MELANOMA$276,378
R21 · FY2007 · CA · contact PI
PEMPHIGUS 2005-PROGRESS AND FUTURE DIRECTIONS$40,000
R13 · FY2005 · AR
POLYVALENT VACCINE IN IL-2+GM-CSF LIPOSOMES FOR MELANOMA$350,675
R01 · FY2004 · CA
Polypeptide Vaccine In IL-2 Liposomes For Prostate Ca$374,727
R01 · FY2002 · CA
POLYVALENT VACCINE IN IL-2+GM-CSF LIPOSOMES FOR MELANOMA$349,638
R01 · FY2002 · CA
POLYVALENT VACCINE IN IL-2+GM-CSF LIPOSOMES FOR MELANOMA$348,600
R01 · FY2001 · CA
PEMPHIGUS AS A MODEL ORGAN-SPECIFIC AUTOIMMUNE DISEASE$40,000
R13 · FY2001 · AR